Alexion Pharmaceuticals, Inc.
8-K on 05/19/2020   Download
SEC Document
SEC Filing
false0000899866 0000899866 2020-05-19 2020-05-19
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_______________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): May 19, 2020
ALEXION PHARMACEUTICALS, INC.
-----------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware
000-27756
13-3648318
------------------
------------------
---------------
(State or other jurisdiction
of incorporation or organization)
(Commission
File Number)
(I.R.S. Employer
Identification No.)

121 Seaport Boulevard, Boston, Massachusetts 02210
---------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code:    (475) 230-2596
   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
ALXN
Nasdaq Global Select Market




Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨







Item 5.07    Submission of Matters to a Vote of Security Holders.

Alexion Pharmaceuticals, Inc. held its Annual Meeting of Shareholders on May 13, 2020. The results of the matters voted on by the shareholders are set forth below.

1.    The election of directors:
 
Votes For
 
Withheld
 
Broker
Non-Votes
 
 
 
 
 
 
Felix Baker
165,892,446
 
12,943,049
 
12,701,782
David R. Brennan
169,233,141
 
9,602,354
 
12,701,782
Christopher J. Coughlin
175,404,484
 
3,431,011
 
12,701,782
Deborah Dunsire
172,928,111
 
5,907,384
 
12,701,782
Paul A. Friedman
103,068,306
 
75,767,189
 
12,701,782
Ludwig N. Hantson
177,092,282
 
1,743,213
 
12,701,782
John T. Mollen
172,013,279
 
6,822,216
 
12,701,782
Francois Nader
158,638,013
 
20,197,482
 
12,701,782
Judith A. Reinsdorf
172,875,464
 
5,960,031
 
12,701,782
Andreas Rummelt
173,823,438
 
5,012,057
 
12,701,782


2.
Ratification of the appointment of PricewaterhouseCoopers LLP as Alexion's independent registered public accounting firm:
Votes For
 
Votes Against
 
Abstentions
189,635,116
 
1,842,994
 
59,167

3.
The non-binding advisory vote to approve the compensation paid to Alexion’s named executive officers as described in Alexion’s 2020 proxy statement:
Votes For
 
Votes Against
 
Abstentions
 
Broker Non-Votes
163,448,951
 
15,237,286
 
149,258
 
12,701,782

4.
Shareholder proposal requesting that the Board of Directors amend provisions set forth in Alexion's By-laws to lower the threshold for shareholders to call a special meeting of shareholders.

Votes For
 

Votes Against
 

Abstentions
 

Broker Non-Votes
85,596,667
 
92,091,767
 
147,061
 
12,701,782

 





Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 19, 2020
 
ALEXION PHARMACEUTICALS, INC.
 
 
By:    /s/ Doug Barry  
Name: Doug Barry
Title: Vice President, Corporate Law